Insmed Incorporated(INSM)
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Latest News & Analysis
Insmed (INSM): Brensocatib's FDA Path, ARIKAYCE Growth, and ATS 2025 Insights
Analysis of Insmed's brensocatib FDA review, ARIKAYCE sales, and ATS 2025 insights. Strategic focus, market performance, and healthcare policy impacts explored.
Insmed (INSM): Brensocatib's FDA Journey, ARIKAYCE's Ascent, and Future Prospects
Insmed (INSM) awaits a pivotal FDA decision on brensocatib for bronchiectasis. Strong ARIKAYCE growth contrasts with wider losses, shaping its future prospects.
Insmed (INSM): Brensocatib FDA Review, ARIKAYCE Growth, and Financial Outlook
Insmed's brensocatib nears potential FDA approval amid strong ARIKAYCE sales. Q4 losses spark caution, but analysts see potential. A deep dive into INSM's outlook.
Insmed (INSM): Brensocatib's FDA Decision Looms - A Comprehensive Analysis
Insmed awaits FDA decision on brensocatib (August 12, 2025). No advisory committee suggests streamlined approval. Q4 loss wider, but ARIKAYCE strong. Key insights inside.
Insmed (INSM): Brensocatib FDA Update, ARIKAYCE Sales, and Market Outlook
Analysis of Insmed (INSM): FDA update on Brensocatib, ARIKAYCE sales, international strategies, and Q4 2024 financials. Actionable insights for investors.